INCREASING OPPORTUNITY FOR INDIVIDUALISED CARE WITH AN ORAL GLP-1RA
Filip Knop (Denmark)
Welcome
Tina Vilsbøll (Denmark)
Innovation in the GLP-1RA landscape: expanding options for individualised care
Juris Meier (Germany)
An oral GLP-1RA in the incretin landscape
Richard Pratley (USA)
Navigating the evolving treatment landscape: head-to-head comparisons
Ofri Mosenzon (Israel)
The vulnerable patient: the use of semaglutide in renal impairment and late stage disease
Stephen Bain (UK)
Diving deeper into the PIONEER programme: exploring different patient populations
All
Clinical perspectives: an oral GLP-1RA to individualise diabetes treatment